SCHEMBL17045244

SCHEMBL17045244

[CH2]C(N)Cc1ccc(OCC)cc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.54
TSHR P16473 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ACACB O00763 4/20 0.44
SLC6A4 P31645 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
PARP10 Q53GL7 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
PRSS1 P07477 1/20 0.43
PRSS2 P07478 1/20 0.43
PRSS3 P35030 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17045265 1.00 NQO1 (0.54) NQO1TSHRTDP1LMNASMN1; SMN2
SCHEMBL2553013 0.82 SLC6A4 (0.66) NQO1SLC6A4
SCHEMBL2553015 0.82 SLC6A4 (0.66) NQO1SLC6A4
SCHEMBL11143074 0.81 NQO1 (0.54) NQO1TSHRTDP1ACACB
SCHEMBL7364325 0.79 NQO1 (0.52) NQO1TSHRTDP1ACACBPARP10
SCHEMBL7364322 0.79 NQO1 (0.52) NQO1TSHRTDP1ACACBPARP10
SCHEMBL28108926 0.79 NQO1 (0.52) NQO1TSHRTDP1ACACBPARP10
SCHEMBL256094 0.78 SLC6A4 (0.59) NQO1SLC6A4
SCHEMBL5018760 0.78 NQO1 (0.61) NQO1TSHRTDP1ACACBSIGMAR1
SCHEMBL14279477 0.77 NQO1 (0.48) NQO1TSHRTDP1ACACBPARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-07-13 US claimed
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS., LTD. 2021-04-22 US claimed
US-10888542-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-01-12 US claimed
US-20200046674-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2020-02-13 US claimed
CN-106458866-B Aminocarbonyl carbamate compound 爱思开生物制药株式会社 2018-12-07 CN claimed
US-9833432-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-12-05 US claimed
EP-3110792-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK Biopharmaceuticals Co., Ltd. (KR) 2017-01-04 EP claimed
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. 2016-10-20 US claimed
US-9403761-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-08-02 US claimed
WO-2015130121-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 WO claimed
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 US claimed
EP-4395763-A1 METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AXSOME THERAPEUTICS (US) 2024-07-10 EP disclosed
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-07-13 US disclosed
WO-2023034944-A1 METHODS AND COMPOSITIONS FOR AMELIORATING BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK USING (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE AXSOME THERAPEUTICS (US) 2023-03-09 WO disclosed
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS., LTD. 2021-04-22 US disclosed
EP-3110792-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK Biopharmaceuticals Co., Ltd. (KR) 2017-01-04 EP disclosed
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. 2016-10-20 US disclosed
US-9403761-B2 Aminocarbonylcarbamate compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-08-02 US disclosed
WO-2015130121-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 WO disclosed
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SK BIOPHARMACEUTICALS CO., LTD. (KR) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246874-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 NQO1 1675/4885TSHR 1727/4885TDP1 2226/4885
US-10888542-B2 Aminocarbonylcarbamate compounds SLC6A3, SLC6A2, SLC6A4 NQO1 1675/4885TSHR 1727/4885TDP1 2226/4885
US-20160303067-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 NQO1 1675/4885TSHR 1727/4885TDP1 2226/4885
US-20210113514-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 NQO1 1675/4885TSHR 1727/4885TDP1 2226/4885
US-20200046674-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 NQO1 1675/4885TSHR 1727/4885TDP1 2226/4885
US-20230218562-A1 AMINOCARBONYLCARBAMATE COMPOUNDS SLC6A3, SLC6A2, SLC6A4 NQO1 1675/4885TSHR 1727/4885TDP1 2226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.